CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 6 incoming connections
- ScaleRevenue is $3.18B, above the global median of $520.53M
- PositionGross margin is 6.7%, lower than 95% of its Pharmaceutical Retailers peers (median 24.3%)
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
3.06%Below 5Y avg (3.25%)
Annual Rate
CNY 0.35Paid annual
Payout Ratio
49.3%Sustainable
Payback Period
31.2 yr
Last Ex-Dividend
Jul 10, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.44BCNY659.54M · vs all stocks (USD)
Trailing P/E
16.49xvs Pharmaceutical Retailers peers
Revenue (TTM)
21.42BCNY3.18B · vs all stocks (USD)
Profit Margin
1.29%vs Pharmaceutical Retailers peers
Beta
-0.0060xvs all stocks
52-Week Change
29.30%vs all stocks
Market Capitalization
4.44BCNY659.54M · vs all stocks (USD)
Enterprise Value
9.23BCNY1.37B · vs all stocks (USD)
Trailing P/E
16.49xvs Pharmaceutical Retailers peers
Price to Sales (TTM)
0.2124xvs Pharmaceutical Retailers peers
Price to Book (MRQ)
1.35xvs Pharmaceutical Retailers peers
Enterprise to Revenue
0.4310xvs Pharmaceutical Retailers peers
Enterprise to EBITDA
14.27xvs Pharmaceutical Retailers peers
Gross Margin
6.71%vs Pharmaceutical Retailers peers
Profit Margin
1.29%vs Pharmaceutical Retailers peers
Operating Margin
2.67%vs Pharmaceutical Retailers peers
Return on Assets (TTM)
2.76%vs Pharmaceutical Retailers peers
Return on Equity (TTM)
8.28%vs Pharmaceutical Retailers peers
Revenue (TTM)
21.42BCNY3.18B · vs all stocks (USD)
Revenue per Share (TTM)
54.80CNYUpdated Aug 20, 2026Quarterly Revenue Growth
3.40%vs Pharmaceutical Retailers peers
Gross Profit (TTM)
1.49BCNY221.97M · vs all stocks (USD)
EBITDA (TTM)
586.44MCNY87.10M · vs all stocks (USD)
Net Income (TTM)
277.50MCNY41.21M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-4.70%vs Pharmaceutical Retailers peers
Operating Cash Flow (TTM)
519.76MCNY77.19M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
193.26MCNY28.70M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.3500CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
3.06%vs all stocks
5-Year Average Dividend Yield
3.25%vs all stocks
Payout Ratio
49.30%vs Pharmaceutical Retailers peers
Minority Interest (Equity)
17.09MCNYFY2025 · Dec 31, 2025Revenue
21.25BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
19.74BCNYFY2025 · Dec 31, 2025Gross Profit
1.50BCNYFY2025 · Dec 31, 2025Operating Income
597.30MCNY88.71M · vs all stocks (USD)
Pre-tax Income
376.23MCNYFY2025 · Dec 31, 2025Income Tax Expense
97.25MCNYFY2025 · Dec 31, 2025Net Income
278.98MCNYFY2025 · Dec 31, 2025EBIT
554.58MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
721.13MCNYFY2025 · Dec 31, 2025Research & Development
6.52MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
136.34MCNYFY2025 · Dec 31, 2025Other Operating Expenses
54.31MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
2.66MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
178.36MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.7200CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.7200CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
390.12MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
390.12MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
278.98MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
1.90MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-155.24MCNYFY2025 · Dec 31, 2025Free Cash Flow
-388.14MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
345.20MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
278.98MCNYFY2025 · Dec 31, 2025Other Non-cash Items
189.44MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-444.37MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-179.29MCNYFY2025 · Dec 31, 2025Capital Expenditures
-232.90MCNYFY2025 · Dec 31, 2025Purchase of Investments
-10.09MCNYFY2025 · Dec 31, 2025Other Investing Activity
-580.07KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-243.58MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
9.50BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-9.55BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-313.96MCNYFY2025 · Dec 31, 2025Other Financing Charges
-76.69MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-439.92MCNYFY2025 · Dec 31, 2025Shares Outstanding
388.52MSharesUpdated Aug 20, 2026Float Shares
232.28MSharesUpdated Aug 20, 2026% Held by Insiders
42.35%vs all stocks
% Held by Institutions
0.46%vs all stocks
Total Cash (MRQ)
555.93MCNY82.57M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.43CNYUpdated Aug 20, 2026Total Debt (MRQ)
5.24BCNY777.83M · vs all stocks (USD)
Total Debt to Equity (MRQ)
1.55xvs Pharmaceutical Retailers peers
Current Ratio (MRQ)
1.11xvs Pharmaceutical Retailers peers
Book Value per Share (MRQ)
8.69CNYUpdated Aug 20, 2026Total Assets
13.40BCNY1.99B · vs all stocks (USD)
Total Current Assets
10.46BCNYFY2025 · Dec 31, 2025Total Liabilities
10.07BCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.94BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
489.30MCNYFY2025 · Dec 31, 2025Total Current Liabilities
9.58BCNYFY2025 · Dec 31, 2025Cash
333.66MCNYFY2025 · Dec 31, 2025Cash Equivalents
283.30MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
616.96MCNYFY2025 · Dec 31, 2025Accounts Receivable
6.36BCNYFY2025 · Dec 31, 2025Inventory
3.04BCNYFY2025 · Dec 31, 2025Accounts Payable
4.71BCNYFY2025 · Dec 31, 2025Short-term Debt
4.48BCNYFY2025 · Dec 31, 2025Other Current Liabilities
2.75MCNYFY2025 · Dec 31, 2025Long-term Debt
408.87MCNYFY2025 · Dec 31, 2025Common Stock (Book)
388.52MCNYFY2025 · Dec 31, 2025Retained Earnings
2.10BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
3.32BCNY493.69M · vs all stocks (USD)
52-Week Low
7.90CNYUpdated Aug 20, 202652-Week High
28.29CNYUpdated Aug 20, 202652-Week Change
29.30%vs all stocks
Beta
-0.0060xvs all stocks
50-Day MA
10.74CNYUpdated Aug 20, 2026200-Day MA
13.87CNYUpdated Aug 20, 2026Avg 10-Day Volume
25.30MSharesUpdated Aug 20, 2026Avg 30-Day Volume
26.01MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
0.7100CNYUpdated Aug 20, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Diagnostic
Elevated ROE With High Debt-to-Equity and Equity Multiplier
Return on equity reads high on a balance sheet carrying a lot of debt against that equity.
Reads
Where is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Elevated Leverage on Three Denominators
Debt sits high against its equity, its assets, and its cash flow.
Reads
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 6.7%, lower than 95% of its Pharmaceutical Retailers peers (median 24.3%)Significant
Gross margin: 0.07Industry median: 0.24Industry P5: 0.07Peers compared: 22.00
Financial Health
Altman Z-Score 2.28: grey zoneSignificant
Altman Z-Score: 2.28
Supply Chain
Midstream position: 5 outgoing, 6 incoming connectionsNotable
Outgoing: 5.00Incoming: 6.00
High connectivity hub: 11 industry connectionsNotable
Total Connections: 11.00
Scale
Revenue is $3.18B, above the global median of $520.53MNotable
Revenue (USD): 3,181,899,323.802Global Median: 520,528,949.311
Levered free cash flow is $28.7M, above the global median of $16.24MNotable
Levered free cash flow (USD): 28,703,517.001Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Arata Corporation
Tier 1FlowUnit ReplicationInterfaceProduction
Farglory Free Trade Zone Investment Holding Company Limited
Tier 1FlowUnit ReplicationProductionInterface
Axial Retailing Inc.
Tier 1FlowUnit ReplicationInterfaceProduction
Shanghai Laiyifen Co., Ltd.
Tier 1FlowUnit ReplicationInterfaceProduction
Cass Information Systems, Inc.
Tier 1FlowUnit ReplicationProductionSenseMaking
DocMorris AG
Tier 1FlowUnit ReplicationProductionInterface
Zhongbai Holdings Group Co., Ltd.
Tier 1FlowUnit ReplicationInterfaceProduction
Halows Co. Ltd.
Tier 1FlowUnit ReplicationInterfaceProduction
Mavi Giyim Sanayi ve Ticaret A.Ş.
Tier 1FlowUnit ReplicationRiskInterface
Wangli Security & Surveillance Co., Ltd.
Tier 1FlowUnit ReplicationProductionRule
Companies that share active interpretations — structural patterns currently present in both stocks.
The Sherwin-Williams Company
2 interpretationsElevated Leverage on Three DenominatorsElevated ROE With High Debt-to-Equity and Equity Multiplier
Pourin Special Welding Technology Co., Ltd.
2 interpretationsPartial Recovery After Sharp DeclineDecline With Range Expansion And Drawdown
Changzheng Engineering Co., Ltd.
2 interpretationsPartial Recovery After Sharp DeclineDecline With Range Expansion And Drawdown